Vanguard amends ownership for Corvus Pharmaceuticals (NASDAQ: CRVS) after realignment

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 1 to a Schedule 13G for Corvus Pharmaceuticals Inc, reporting 0 shares beneficially owned of Common Stock and 0% ownership as stated in the amendment dated 03/13/2026. The filing states Vanguard reorganized internally on January 12, 2026, and certain subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538.

The signature block shows the filing was signed by Ashley Grim, Head of Global Fund Administration, on 03/26/2026.

Insights

Institutional Ownership Analyst

Amendment documents zero beneficial ownership and a Vanguard internal realignment.

The filing lists Amount beneficially owned: 0 and Percent of class: 0% as of the amendment dated 03/13/2026. It cites the January 12, 2026 internal realignment and SEC Release No. 34-39538 to explain disaggregation of certain subsidiaries.

Cash‑flow treatment or any sales/purchases are not stated in the excerpt; subsequent filings from Vanguard or the reporting subsidiaries would show any active positions or transactions.

Registry & Compliance Specialist

Regulatory note: the amendment documents deaggregation under SEC guidance.

The text explicitly references SEC Release No. 34-39538 and describes that subsidiaries will report separately and that Vanguard no longer is deemed to beneficially own those subsidiary holdings. This is a procedural ownership reallocation, not an economic transaction disclosed here.

Monitor subsequent Schedule 13 filings from the named Vanguard entities for any nonzero holdings; timing and amounts are not provided in this amendment.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Corvus Pharmaceuticals Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

(CUSIP Number)

03/13/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Corvus Pharmaceuticals Inc
(b)	Address of issuer's principal executive offices: 863 Mitten Road, Suite 102, Burlingame, CA, 94010
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd.,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.:
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	03/26/2026

FAQ

What does Vanguard report for CRVS ownership in this amendment?

The amendment states Amount beneficially owned: 0 and Percent of class: 0%. It indicates Vanguard disaggregated certain subsidiaries following an internal realignment on January 12, 2026 per SEC Release No. 34-39538.

When was the Vanguard internal realignment referenced in the Schedule 13G/A?

The filing cites an internal realignment on January 12, 2026. That date is referenced as the basis for separate reporting by certain Vanguard subsidiaries under SEC Release No. 34-39538.

Who signed the amendment for The Vanguard Group on behalf of CRVS reporting?

The amendment is signed by Ashley Grim, Head of Global Fund Administration, with the signature date shown as 03/26/2026, per the document's signature block.

Does this amendment show any purchases or sales of Corvus Pharmaceuticals (CRVS) shares?

No; the amendment lists 0 shares beneficially owned and does not disclose any purchases or sales. The excerpt provides no transaction or cash‑flow details.

Why are Vanguard subsidiaries reporting separately after the realignment?

The filing states subsidiaries will report disaggregated ownership in reliance on SEC Release No. 34-39538, meaning certain previously aggregated holdings are now reported separately following the internal reorganization.